| 1 |
35151642 | ATRA promotes PD-L1 expression to control gastric cancer immune surveillance. | 2022 Apr 5 |
2 |
| 2 |
33341940 | Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. | 2021 Feb |
3 |
| 3 |
33965175 | Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. | 2021 May |
1 |
| 4 |
34422627 | CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. | 2021 |
1 |
| 5 |
34733993 | CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. | 2021 Sep |
1 |
| 6 |
31867003 | JAK Inhibitors and Oxidative Stress Control. | 2019 |
1 |
| 7 |
29933930 | JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. | 2018 Oct |
2 |
| 8 |
30035369 | Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. | 2018 Nov |
1 |